Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a sell rating in a research report released on Saturday.

Several other brokerages also recently weighed in on RVPH. Maxim Group lowered their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Friday. Citigroup restated a “buy” rating on shares of Reviva Pharmaceuticals in a research note on Friday. Finally, D. Boral Capital restated a “buy” rating and set a $3.00 target price on shares of Reviva Pharmaceuticals in a research note on Friday, June 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $8.00.

Reviva Pharmaceuticals Price Performance

NASDAQ:RVPH opened at $0.54 on Friday. The business’s 50-day moving average is $0.51 and its two-hundred day moving average is $0.89. Reviva Pharmaceuticals has a 12 month low of $0.30 and a 12 month high of $4.28. The firm has a market capitalization of $25.92 million, a PE ratio of -0.83 and a beta of -0.05.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. Equities analysts anticipate that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in Reviva Pharmaceuticals in the fourth quarter worth about $25,000. Cornerstone Select Advisors LLC acquired a new position in Reviva Pharmaceuticals in the fourth quarter worth about $32,000. XTX Topco Ltd acquired a new position in Reviva Pharmaceuticals in the fourth quarter worth about $45,000. Tower Research Capital LLC TRC grew its stake in Reviva Pharmaceuticals by 848.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after purchasing an additional 23,953 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in Reviva Pharmaceuticals in the fourth quarter worth about $84,000. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.